aXichem AB (publ), a developer of natural analogue industrial compounds, is participating in Vitafoods Europe 2021, 5–7 October, in Geneva. Vitafoods is one of Europe’s biggest events and attracts players from all areas of the nutraceutical industry. aXichem will present its unique phenylcapsaicin product, aXivite, supported by the solid results from the clinical trial “Effects of Phenyl-Capsaicin on Weight Loss and Body Composition” conducted at the Center for Applied Health Sciences in Ohio and communicated earlier this year. aXichem will participate in-person, in booth # K264, as well as at the on-line event at this hybrid version of Vitafoods Europe.
– I’m thrilled that we are now able to meet partners and customers in person again. Vitafoods is an excellent show for us and for our newly established network of European distributors. We are here together with all the leading players in the growing field of nutraceuticals and I’m looking forward to present aXivite and the documented benefits of our commercially ready and approved product, says Lucas Altepost, Vice President and VP Sales and Marketing at aXichem.
About aXivite and the clinical trial “Effects of Phenyl-Capsaicin on Weight Loss and Body Composition”: aXivite (phenylcapsaicin) is a novel functional ingredient derived from the natural compound, capsaicin. In a recently completed healthy human, blinded, randomized, clinical study, aXivite demonstrated statistically significant body fat loss, an improved body-shape and lean mass profile and improved gut health, as measured by a decrease in serum zonulin. At both the low and high dose tested, aXivite showed excellent tolerability and safety profile over the 8 week treatment period.
The eight-week study was conducted as a randomized, double-blind, parallel-group clinical trial of male and female subjects recruited at a single investigational center in Northeast Ohio. The study was conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data. 39 patients completed the study - 12 placebo treated, 15 high dose (1,12 mg/day) aXivite treated and 12 low dose (0,560 mg/day) aXivite treated.
aXivite is a well-studied synthetic capsaicin which is being developed for multiple nutraceutical and pharmaceutical applications. aXivite’s gut-health mechanism of action is particularly associated with reduced inflammation, occurring via a statistically significant reduction in serum zonulin levels. This clinical study has demonstrated a metabolic role for aXivite that induces increased fat-burn leading to healthy weight loss and body shape in healthy subjects. Unpublished and published data with aXivite treatment, including this clinical study, continue to demonstrate an excellent safety and tolerability profile at both high (1,12 mg/day) and low (0,560mg/day) doses.
About Vitafoods Europe: Vitafoods Europe started 1997 to meet the growing demands of the emerging nutraceutical industry. CEO and Founder, Nick Hawker, believed there was a need for a dedicated exhibition and scientific conference to fill a gap in the market at the time.2019 edition of Vitafoods Europe welcomed more than 1,250 exhibitors in 23,000 square meters of floor space and gathered over 25,000 visitors in the Palexpo Exhibition Hall.This annual gathering sees a global audience across four sectors covering the entire nutraceutical supply chain, from beginning to end.
This press release was submitted by the contact person below on 13 September 2021, at 09:00 AM CET.